Syntax Bio Announces Collaboration with Mayo Clinic to Advance Pancreatic Cell Therapy for Type 1 Diabetes
Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes.
Syntax Bio Receives Award from Breakthrough T1D to Advance Pancreatic Beta Cell Therapy for Type 1 Diabetes
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an award of up to $856,250 from Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, under its Industry Discovery and Development Partnership (IDDP) program to advance a pancreatic beta cell therapy targeting T1D using its Cellgorithm platform technology.
New Research Highlights Syntax Bio’s Platform for Simple Yet Powerful Programming of Human Stem Cells
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based Cellgorithm™ technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today.
Syntax Bio Launches with Strategic Backing from Astellas Venture Management LLC and Illumina Ventures
Syntax Bio, a preclinical-stage biotechnology company, has launched with backing from Astellas Venture Management LLC and Illumina Ventures. Other investors include DCVCBio, Civilization Ventures, EGB Capital, and Portal Innovations.
